Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromhexine and Spironolactone for COVID-19
NCT04424134Phase 3Unknown
- Sponsor
- Lomonosov Moscow State University Medical Research and Educational Center
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bromhexine and spironolactone in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Lomonosov Moscow State University Medical Research and Educational Center. Primary endpoint: Change from baseline in clinical assessment score COVID 19 at 12 days. Status: unknown.
02
Drugs
bromhexinespironolactone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04424134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04424134.